title: The College of American Pathologists' first 3 years' experience with high-risk human papillomavirus proficiency testing for cytology and other laboratories.
abstract: BACKGROUND
  The College of American Pathologists (CAP) Human Papillomavirus (High-Risk) Survey for Cytopathology and Other Laboratories (CHPV) meets the Clinical Laboratory Improvement Amendments of 1988 (CLIA '88) requirements for 5 proficiency testing challenges analyzed 3 times per year. This study reports laboratory performance for CHPV from 2008 through 2010.
  
  
  OBJECTIVE
  To identify trends in proficiency testing performance for subscribers to the CAP CHPV.
  
  
  METHODS
  CHPV responses were evaluated by using a nonlinear mixed model (significance level of .05) with a 2-factor interaction term and repeated measures component, comparing year, media, method, and intended response. Media types included Digene transport, SurePath, ThinPrep media, or a mixture of media types. Proficiency testing challenges validated at 80% consensus.
  
  
  RESULTS
  All challenges validated; 476 laboratories submitted 14 911 responses with 14 620 correct responses (98%). There were no differences between positive or negative challenges, or rate of correct responses; significant differences existed between media types by year and methods. Digene and ThinPrep media performed better than SurePath (P < .001; P = .03). There was a statistically significant difference between methods (P < .001); "other commercial kits," "other (noncommercial)" tests, and Third Wave performed more poorly than others.
  
  
  CONCLUSIONS
  Laboratories performed well when testing for human papillomavirus in CHPV during a period of 3 years. All challenges performed to the 80% threshold. Significant differences were found between methods and media. The CAP CHPV survey provides useful information for laboratories choosing human papillomavirus testing methods.
authors.affiliation: Department of Esoteric Testing, AmeriPath Indiana, IN, USA. Amoriarty@ameripath.com
authors.forename: Ann T
authors.initials: AT
authors.lastname: Moriarty
authors.forename: Joel S
authors.initials: JS
authors.lastname: Bentz
authors.forename: Barbara
authors.initials: B
authors.lastname: Winkler
authors.forename: Andrew H
authors.initials: AH
authors.lastname: Fischer
authors.forename: Rodolfo
authors.initials: R
authors.lastname: Laucirica
authors.forename: Rhona J
authors.initials: RJ
authors.lastname: Souers
authors.forename: Nicole
authors.initials: N
authors.lastname: Thomas
authors.forename: Chengquan
authors.initials: C
authors.lastname: Zhao
mesh_terms: D003581:Cytodiagnosis / Q000592:standards*; D005260:Female; D006801:Humans; D059021:Laboratory Proficiency Testing; D030361:Papillomavirus Infections / Q000175:diagnosis*; D014626:Vaginal Smears / Q000592:standards*